Royce & Associates LP Purchases 3,274 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

Royce & Associates LP raised its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 11.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,567 shares of the company's stock after acquiring an additional 3,274 shares during the quarter. Royce & Associates LP owned approximately 0.11% of GeneDx worth $2,426,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Fred Alger Management LLC bought a new position in shares of GeneDx in the third quarter valued at $16,731,000. Zweig DiMenna Associates LLC bought a new stake in shares of GeneDx in the 4th quarter valued at about $23,788,000. Raymond James Financial Inc. acquired a new stake in GeneDx in the 4th quarter valued at about $20,371,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in GeneDx during the third quarter worth approximately $7,533,000. Finally, Summit Partners Public Asset Management LLC bought a new stake in GeneDx in the third quarter valued at approximately $7,340,000. Institutional investors own 61.72% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. The Goldman Sachs Group boosted their target price on GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a report on Wednesday, February 19th. TD Cowen lifted their target price on shares of GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $72.33.

Remove Ads

Insider Buying and Selling

In other news, CEO Katherine Stueland sold 51,420 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60. Following the completion of the transaction, the chief executive officer now directly owns 1,720 shares in the company, valued at approximately $162,505.60. This represents a 96.76 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kevin Feeley sold 1,430 shares of the company's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $76.04, for a total value of $108,737.20. Following the completion of the transaction, the chief financial officer now directly owns 26,770 shares of the company's stock, valued at approximately $2,035,590.80. The trade was a 5.07 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 127,735 shares of company stock worth $11,719,787. Corporate insiders own 27.30% of the company's stock.

GeneDx Stock Performance

NASDAQ WGS traded down $2.60 during trading on Tuesday, reaching $100.59. The company's stock had a trading volume of 505,756 shares, compared to its average volume of 620,520. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 12 month low of $8.10 and a 12 month high of $115.60. The firm has a 50 day moving average price of $85.25 and a 200 day moving average price of $72.73. The firm has a market capitalization of $2.82 billion, a price-to-earnings ratio of -51.32 and a beta of 1.91.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million during the quarter, compared to analysts' expectations of $82.24 million. As a group, equities analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.